UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds

Drug metabolism and disposition, 2018-11, Vol.46 (11), p.1466-1477

2018

Volltextzugriff (PDF)

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

Journal of medicinal chemistry, 2018-09, Vol.61 (18), p.8120-8135

2018

Volltextzugriff (PDF)

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Nature (London), 2017-03, Vol.543 (7647), p.733-737

2017

Volltextzugriff (PDF)

Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance

Journal of clinical pharmacology, 2013-02, Vol.53 (2), p.178-191

2013

Volltextzugriff (PDF)

An Accurate In Vitro Prediction of Human VDss Based on the Øie–Tozer Equation and Primary Physicochemical Descriptors. 3. Analysis and Assessment of Predictivity on a Large Dataset

Drug metabolism and disposition, 2019-12, Vol.47 (12), p.1380-1387

2019

Volltextzugriff (PDF)

Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State

Journal of clinical pharmacology, 2013-02, Vol.53 (2), p.167-177

2013

Volltextzugriff (PDF)

An Accurate In Vitro Prediction of Human VD ss Based on the Øie-Tozer Equation and Primary Physicochemical Descriptors. 3. Analysis and Assessment of Predictivity on a Large Dataset

Drug metabolism and disposition, 2019-12, Vol.47 (12), p.1380-1387

2019

Volltextzugriff (PDF)

In Silico Models of Human PK Parameters. Prediction of Volume of Distribution Using an Extensive Data Set and a Reduced Number of Parameters

Journal of pharmaceutical sciences, 2021-01, Vol.110 (1), p.500-509

2021

Volltextzugriff (PDF)

Prediction of Human Clearance Using In Silico Models with Reduced Bias

Molecular pharmaceutics, 2024-03, Vol.21 (3), p.1192-1203

2024

Volltextzugriff (PDF)

In silico Prediction of Total Human Plasma Clearance

Journal of chemical information and modeling, 2012-08, Vol.52 (8), p.2069-2078

2012

Volltextzugriff (PDF)

Evolution of the physicochemical properties of marketed drugs: can history foretell the future?

Drug discovery today, 2011-11, Vol.16 (21), p.976-984

2011

Volltextzugriff (PDF)

Clearance Mechanism Assignment and Total Clearance Prediction in Human Based upon in Silico Models

Journal of medicinal chemistry, 2014-05, Vol.57 (10), p.4397-4405

2014

Volltextzugriff (PDF)

In Silico Prediction of Volume of Distribution in Human Using Linear and Nonlinear Models on a 669 Compound Data Set

Journal of medicinal chemistry, 2009-07, Vol.52 (14), p.4488-4495

2009

Volltextzugriff (PDF)

Design and synthesis of trans 2-(furan-2-yl)vinyl heteroaromatic iodides with antitumour activity

Bioorganic & medicinal chemistry, 2008-04, Vol.16 (7), p.4150-4159

2008

Volltextzugriff (PDF)

Systematic Evaluation of Wajima Superposition (Steady-State Concentration to Mean Residence Time) in the Estimation of Human Intravenous Pharmacokinetic Profile

Journal of pharmaceutical sciences, 2016-03, Vol.105 (3), p.1277-1287

2016

Volltextzugriff (PDF)

Pharmacophore, Drug Metabolism, and Pharmacokinetics Models on Non-Peptide AT1, AT2, and AT1/AT2 Angiotensin II Receptor Antagonists

Journal of medicinal chemistry, 2005-06, Vol.48 (13), p.4389-4399

2005

Volltextzugriff (PDF)

Benefit of Retraining pK a Models Studied Using Internally Measured Data

Journal of chemical information and modeling, 2015-07

2015

Volltextzugriff (PDF)

Systematic Evaluation of Wajima Superposition (Steady-State Concentration to Mean Residence Time) in the Estimation of Human Intravenous Pharmacokinetic Profile: Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism

Journal of pharmaceutical sciences, 2016-03, Vol.105 (3), p.1277-1287

2016

Volltextzugriff (PDF)

Benefit of Retraining pKa Models Studied Using Internally Measured Data

Journal of chemical information and modeling, 2015-07, Vol.55 (7), p.1449-1459

2015

Volltextzugriff (PDF)

Benefit of Retraining pK^sub a^ Models Studied Using Internally Measured Data

Journal of chemical information and modeling, 2015-07, Vol.55 (7), p.1449

2015

Volltextzugriff (PDF)

Benefit of Retraining p K a Models Studied Using Internally Measured Data

Journal of chemical information and modeling, 2015-07, Vol.55 (7), p.1449-1459

2015

Volltextzugriff (PDF)

The allosteric inhibitor ABL001 enables dual targeting of BCRABL1

Nature (London), 2017-03, Vol.543 (7647), p.733

2017

Volltextzugriff (PDF)

Pharmacophore, Drug Metabolism, and Pharmacokinetics Models on Non-Peptide AT 1 , AT 2 , and AT 1 /AT 2 Angiotensin II Receptor Antagonists

Journal of medicinal chemistry, 2005-06, Vol.48 (13), p.4389-4399

2005

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(26)
Buchkapitel
(2)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(17)
Pharmacology & Pharmacy
(17)
Humans
(12)
Chemistry, Medicinal
(10)
Animals
(8)
Biological And Medical Sciences
(6)
Pharmacokinetics
(6)
Rats
(6)
Chemistry
(5)
Medical Sciences
(5)
Pharmacology. Drug Treatments
(5)
Physical Sciences
(5)
Chemistry, Multidisciplinary
(4)
Dogs
(4)
Haplorhini
(4)
Pharmaceutical Preparations - Metabolism
(4)
Chemical Phenomena
(3)
Least-Squares Analysis
(3)
Metabolic Clearance Rate
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation

Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 2: Clearance

An Accurate In Vitro Prediction of Human VDss Based on the Øie–Tozer Equation and Primary Physicochemical Descriptors. 3. Analysis and Assessment of Predictivity on a Large Dataset

Comprehensive Assessment of Human Pharmacokinetic Prediction Based on In Vivo Animal Pharmacokinetic Data, Part 1: Volume of Distribution at Steady State

An Accurate In Vitro Prediction of Human VD ss Based on the Øie-Tozer Equation and Primary Physicochemical Descriptors. 3. Analysis and Assessment of Predictivity on a Large Dataset

In Silico Models of Human PK Parameters. Prediction of Volume of Distribution Using an Extensive Data Set and a Reduced Number of Parameters

Prediction of Human Clearance Using In Silico Models with Reduced Bias

In silico Prediction of Total Human Plasma Clearance

Evolution of the physicochemical properties of marketed drugs: can history foretell the future?

Clearance Mechanism Assignment and Total Clearance Prediction in Human Based upon in Silico Models

In Silico Prediction of Volume of Distribution in Human Using Linear and Nonlinear Models on a 669 Compound Data Set

Design and synthesis of trans 2-(furan-2-yl)vinyl heteroaromatic iodides with antitumour activity

Systematic Evaluation of Wajima Superposition (Steady-State Concentration to Mean Residence Time) in the Estimation of Human Intravenous Pharmacokinetic Profile

Pharmacophore, Drug Metabolism, and Pharmacokinetics Models on Non-Peptide AT1, AT2, and AT1/AT2 Angiotensin II Receptor Antagonists

Benefit of Retraining pK a Models Studied Using Internally Measured Data

Systematic Evaluation of Wajima Superposition (Steady-State Concentration to Mean Residence Time) in the Estimation of Human Intravenous Pharmacokinetic Profile: Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism

Benefit of Retraining pKa Models Studied Using Internally Measured Data

Benefit of Retraining pK^sub a^ Models Studied Using Internally Measured Data

Benefit of Retraining p K a Models Studied Using Internally Measured Data

The allosteric inhibitor ABL001 enables dual targeting of BCRABL1

ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia

Pharmacophore, Drug Metabolism, and Pharmacokinetics Models on Non-Peptide AT 1 , AT 2 , and AT 1 /AT 2 Angiotensin II Receptor Antagonists

Suchergebnisse filtern